Chris Seagle has over 15 years in the pharmaceutical and biotech industry. He is currently the Vice President of Portfolio Strategy at Coherus Biosciences and leads activities related to launch readiness and post-launch commercialization for biosimilars and novel therapeutics. His focus is creating commercial approaches that reduce cost and increase access to biologic therapies for employers and their employees with commercial insurance as well as for patients receiving health care from Medicare, VA, DOD, Medicaid, and other public payers. Chris has worked in the past with PTC Therapeutics, AbbVie, EMD Serono, and Sanofi. He holds both masters and doctoral degrees in Biomedical Engineering from the University of North Carolina at Chapel Hill as well as an MBA from the UNC Kenan-Flagler Business School.